Research programme: antiviral therapeutics - Dominari Holdings
Latest Information Update: 28 Dec 2024
At a glance
- Originator University of Maryland, Baltimore
- Developer Dominari Holdings; University of Maryland, Baltimore
- Class Antivirals; Small molecules
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Coronavirus infections; COVID 2019 infections; Ebola virus infections; Influenza virus infections; Marburg virus disease; Middle East respiratory syndrome coronavirus
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Coronavirus-infections in USA
- 28 Dec 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA
- 28 Dec 2024 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA